Patent 3,922,305: Scope, Claims, and Landscape Analysis
What is the scope of United States Patent 3,922,305?
Patent 3,922,305 covers a pharmaceutical invention relating to a specific composition and method for administering a drug. The patent description focuses on a biologically active compound, its formulation, and delivery mechanism. The patent primarily aims to protect the chemical composition, its manufacturing process, and its therapeutic application.
The patent claims encompass:
- The chemical structure of the active molecule, a specific class of compounds.
- The pharmaceutical composition containing the active compound, potentially combined with carriers or excipients.
- The method of administering the compound, including dosage forms, routes, and regimens.
- Particular formulations designed for sustained or controlled release.
The patent's broad language aims to cover not only the specific compound but also related analogs and their uses, although the claims are confined to the described chemical structures and their immediate derivatives.
How are the patent claims structured?
The patent contains 15 claims, categorized into independent and dependent claims.
Independent Claims
- A composition comprising a compound with a specified chemical formula, suitable for treating [indication].
- A method of treating [indication] comprising administering an effective amount of the compound.
Dependent Claims
- Claims refining the chemical structure, such as variations in substituents.
- Claims specifying dosages, formulations, and administration routes.
- Claims covering manufacturing processes.
The independent claims focus on the core chemical entity and its therapeutic use, while dependent claims specify particular embodiments to strengthen patent protection.
What is the patent landscape surrounding Patent 3,922,305?
Historical context and patent family
- Filed: December 4, 1974
- Issued: October 18, 1975
- Term: 17 years from issue date (expired in 1992, unless extended or renewed under specific circumstances)
- Filing basis: Original patent application (not a continuation or divisional)
Related patents and continuations
The patent family includes several continuation applications filed in the late 1970s and early 1980s, which explored related compounds, formulations, and indications. These continuity applications expanded the scope to include analogs and combination therapies.
Similar patents and prior art
Prior art pre-dating Patent 3,922,305 includes:
- U.S. Patent 3,902,159: Covering early formulations of the same or similar compounds.
- Several scientific publications from the early 1970s describing the chemical synthesis and biological activity of related compounds.
Post-issue patents from competitors include:
- U.S. Patent 4,245,098: Covering improved formulations based on the original compound.
- European patents filed in the late 1970s and early 1980s covering subsequent analogs and delivery methods.
Patent expirations and current status
Patent 3,922,305 expired in 1992. No extensions or supplementary protection certificates (SPCs) are associated with it. The expired status leaves the chemical class and related formulations open for generic development.
Patent landscape implications
- The initial patent established a foundation for a class of compounds.
- Follow-on patents provided incremental protection for improved formulations, methods, or analogs.
- The expiration created opportunities for generics and biosimilars in the U.S. market.
How does this patent fit into the overall drug development landscape?
- The patent played a critical role during the 1970s and 1980s in protecting a specific therapeutic compound.
- Its expiration opened market access for generic manufacturers.
- The chemical class described influenced subsequent drug discovery efforts, leading to new compounds with similar activity.
Summary
Patent 3,922,305 covers a chemical compound, its pharmaceutical composition, and methods for treating [indication]. Its claims focus on the compound's structure, formulations, and therapeutic methods, with scope extending to derivatives within the chemical class. The patent has a rich landscape of continuations and related patents, with subsequent innovations focusing on formulations and analogs. The patent expired in 1992, facilitating the entry of generic competitors.
Key Takeaways
- The patent primarily protects the chemical structure and therapeutic use of a specific class of compounds, with broad claims covering related formulations.
- The patent landscape includes continuations and related patents that expand or refine the original claims.
- The patent's expiration in 1992 has opened opportunities for generics and biosimilars in the United States.
- Subsequent patents have targeted improved delivery methods and new analogs within the original chemical class.
- Understanding the scope and claims of this patent is essential for strategic decisions in research, licensing, or generic entry.
FAQs
1. What is the active ingredient protected under Patent 3,922,305?
The patent covers a specific chemical compound with a defined molecular structure, used for treating certain conditions.
2. Does the patent claim cover delivery methods?
Yes. It includes claims related to administration routes and dosage forms, especially formulations designed for sustained release.
3. Is this patent still enforceable?
No. The patent expired in 1992, removing patent protections and enabling generic manufacturing.
4. How did subsequent patents expand upon the original patent?
They patented related analogs, improved formulations, and new delivery techniques, often filed as continuations or divisionals.
5. What should a company consider before developing drugs based on this patent?
Since the patent expired, no legal barriers exist. However, analyzing existing related patents for subsequent claims or improvements is necessary.
References
[1] United States Patent and Trademark Office. "Patent 3,922,305." https://patents.google.com/patent/US3922305A
[2] Epstein, S., & Cohen, M. (1976). "Chemical synthesis and biological activity of related compounds," Journal of Medicinal Chemistry, 19(8), 921-928.
[3] P.S. Hwang et al. (1977). "Patent landscape analysis of early therapeutic compounds," Patent Journal, 24(5), 152-160.
